WallStSmart

Innovative Eyewear Inc. (LUCY)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 107962% more annual revenue ($3.22B vs $2.98M). WST leads profitability with a 16.9% profit margin vs -272.5%. WST earns a higher WallStSmart Score of 65/100 (C+).

LUCY

Hold

38

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: -0.61

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LUCYUndervalued (+40.5%)

Margin of Safety

+40.5%

Fair Value

$1.85

Current Price

$0.78

$1.07 discount

UndervaluedFair: $1.85Overvalued
WSTSignificantly Overvalued (-55.4%)

Margin of Safety

-55.4%

Fair Value

$158.40

Current Price

$346.56

$188.16 premium

UndervaluedFair: $158.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LUCY3 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
70.2%10/10

Revenue surging 70.2% year-over-year

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

WST5 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

LUCY4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.12M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-102.4%2/10

ROE of -102.4% — below average capital efficiency

Free Cash FlowQuality
$-2.55M2/10

Negative free cash flow — burning cash

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.2x4/10

Trading at 8.2x book value

PEG RatioValuation
3.242/10

Expensive relative to growth rate

P/E RatioValuation
45.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : LUCY

The strongest argument for LUCY centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 70.2% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : LUCY

The primary concerns for LUCY are EPS Growth, Market Cap, Return on Equity.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 45.0x leaves little room for execution misses.

Key Dynamics to Monitor

LUCY profiles as a hypergrowth stock while WST is a growth play — different risk/reward profiles.

LUCY carries more volatility with a beta of 2.70 — expect wider price swings.

LUCY is growing revenue faster at 70.2% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

WST scores higher overall (65/100 vs 38/100), backed by strong 16.9% margins and 21.0% revenue growth. LUCY offers better value entry with a 40.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Innovative Eyewear Inc.

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Innovative Eyewear Inc. (LUCY) stands at the forefront of the smart eyewear sector, merging advanced technology with appealing aesthetics to meet the needs of modern, tech-savvy consumers. Its flagship product line, Lucyd, is designed to provide integrated audio features and seamless connectivity, offering a blend of convenience and style. Firmly focused on enhancing user experience and driving innovation, LUCY is well-positioned to leverage the growing demand for multifunctional eyewear, creating significant growth opportunities in a rapidly evolving market. As the trend towards smart, connected devices accelerates, LUCY’s strategic initiatives to promote its product offerings place it in a strong position for long-term competitiveness and success.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?